Supplementary Figure 2 from &lt;i&gt;ESR1&lt;/i&gt; Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials